Whether the increased incidence of chronic kidney disease (CKD) during intensive systolic blood pressure (SBP) lowering is accompanied by intrinsic kidney injury is unknown.
T
he association of lower blood pressures with substantial cardiovascular and mortality benefit is well established (1) (2) (3) . SPRINT (Systolic Blood Pressure Intervention Trial) was a pivotal randomized controlled trial demonstrating that intensive systolic blood pressure (SBP) reduction to less than 120 mm Hg decreased rates of major cardiovascular events and all-cause mortality compared with standard management to less than 140 mm Hg (4) . Despite these benefits, a notable harm was a more than 3-fold incidence of chronic kidney disease (CKD) in the intensive versus the standard group. Nonetheless, recent guidelines by the American College of Cardiology and American Heart Association lowered blood pressure targets for hypertension diagnosis and management (5) . These policy changes may dramatically increase the incidence of CKD at the population level and pose an important public health concern. However, in the setting of intensive blood pressure lowering, kidney function decline measured by creatinine levels may be a benign manifestation of reduced renal blood flow. Thus, uncertainty remains regarding whether incident CKD that develops during intensive blood pressure lowering is accompanied by intrinsic kidney injury or instead reflects hemodynamic changes.
To address this question, we designed a nested case-control study of incident CKD case participants and matched control participants within SPRINT. We used a panel of urinary biomarkers of kidney damage measured at baseline and at 1 year of follow-up. Our aims were to determine whether baseline biomarker concentrations were associated with incident CKD, whether changes in urinary biomarkers were associated with risk for incident CKD, and whether the extent of biomarker changes differed between participants with CKD that developed during intensive versus standard SBP management. We hypothesized that biomarker changes among CKD case participants in the intensive See also:
Web-Only Supplement

ORIGINAL RESEARCH
Annals of Internal Medicine
group would represent benign changes in renal blood flow rather than intrinsic tissue injury.
METHODS
Study Design and Population
SPRINT was a randomized, controlled, open-label study of intensive (targeting <120 mm Hg) versus standard (targeting <140 mm Hg) SBP therapy in persons at high cardiovascular risk and without diabetes (4) . A total of 9361 participants were enrolled between November 2010 and March 2013 at 102 sites in the United States and Puerto Rico. Among these participants, 2646 (28%) had baseline CKD, defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m 2 by the Modification of Diet in Renal Disease (MDRD) equation. Full details of the study protocols are published elsewhere (6) .
Among participants without CKD at baseline, the SPRINT protocol defined incident CKD as a reduction in eGFR of 30% or more from baseline, on the basis of the MDRD equation, and an eGFR less than 60 mL/min/ 1.73 m 2 confirmed on 2 serial measurements at least 3 months apart. During a mean SPRINT follow-up of 3.26 years, incident CKD developed in 162 participants, 128 in the intensive and 34 in the standard group. Of the 162 incident CKD cases, 26.5% (n = 43) were diagnosed by the 1-year follow-up visit, whereas the remaining cases were diagnosed afterward. In the SPRINT Kidney Tubule Health ancillary project, we defined baseline CKD by using the CKD Epidemiology Collaboration equation with both cystatin C and creatinine (resulting in 2503 cases of baseline CKD), which accounts for the modest difference in the number of incident CKD cases in our study (n = 162) relative to the original publication (n = 154). For each incident CKD case participant, we used prevalent control sampling to select 1 matched control participant in whom CKD had not developed by the end of follow-up. We used a hierarchical matching scheme prioritizing the following factors, in order-randomization group, age (within 5 years), sex, race, and baseline eGFR (within 5 mL/min/ 1.73 m 2 )-to account for these potential confounders. One control participant could not be matched on race after being matched on randomization group, eGFR, and age. The SPRINT Research Group approved the study protocol, which complies with the Declaration of Helsinki.
Measurement of Urinary Biomarkers of Kidney Damage
Our panel included the following 9 urinary biomarkers: albumin-creatinine ratio (ACR), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), anti-chitinase-3-like protein 1 (YKL-40), ␤ 2 -microglobulin (␤ 2 M), ␣ 1 -microglobulin (␣ 1 M), and uromodulin. These proteins have been well studied in kidney disease as direct markers of kidney damage, particularly in the settings of drug nephrotoxocity (7, 8) and acute kidney injury (9 -11). In general, the biomarkers reflect glomerular injury (ACR), tubular injury and fibrosis (IL-18, KIM-1, NGAL, and MCP-1), tubular injury repair (YKL-40), proximal tubular dysfunction (␤ 2 M and ␣ 1 M), and loop of Henle protein production (uromodulin).
We used urine specimens collected from CKD case and control participants at randomization (baseline) and at the 1-year follow-up visit. All specimens were stored continuously at Ϫ80°C, without previous freezethaw, until measurement. Biomarkers were measured at the University of Vermont Laboratory for Clinical Biochemistry Research. Urinary biomarkers from both baseline and 1 year were measured contemporaneously to minimize the influence of laboratory drift. Biomarkers were measured simultaneously by using multiplex immunoassays from Meso Scale Discovery-except for ␣ 1 M, which was measured by using the BN II nephelometer assay (Siemens). Urinary creatinine was measured by using a Cobas c 311 clinical analyzer (Roche Diagnostics). Details regarding assay methods are shown in Appendix Tables 1 and 2 (available at Annals .org). Biomarker concentrations below the lower limit of detection were imputed with a value calculated by subtracting a small number from the limit of detection. Laboratory personnel were blinded to clinical information about the participants, and specimens were evaluated in random order. Except for urinary ACR and ␣ 1 M, all biomarkers were measured in duplicate, and results were averaged to improve precision.
Covariates
In addition to matching factors, covariates examined included baseline and 1-year SBP and diastolic blood pressure; number of antihypertensive medications used; angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker use; and baseline total and high-density lipoprotein cholesterol concentrations, body mass index, history of clinical cardiovascular disease, history of chronic heart failure, and smoking status. Covariates were selected on the basis of evidence from previous studies (12) and were collected as part of the parent trial. Our prespecified analytic plan included statistical adjustments for baseline covariates that differed between case and control participants within each intervention group.
Statistical Analysis
First, we summarized baseline characteristics in CKD case and matched control participants, stratified by intervention group, and tested for differences by using univariate conditional logistic regression models. Next, we compared baseline biomarker concentrations between case and matched control participants in our overall study sample, as well as stratified by intervention group, by fitting separate conditional logistic regression models for each biomarker, adjusting for baseline SBP and urinary creatinine levels. Because of their skewed distributions, biomarker concentrations were summarized by using geometric means and SEs. All models, except those for ACR, were adjusted for log 2 -transformed urinary creatinine concentrations to account for urine tonicity.
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We assessed the potential for bias due to the choice of prevalent control sampling at the end of follow-up rather than incidence density sampling. To account for these potential control selection biases, we used the semiparametric weighted estimator proposed by Landsman and Graubard (13). We then recalculated the associations between biomarkers at baseline and case-control status by using sample weights. Case participants were assigned a weight of 1, because all participants with incident CKD were included in the sample. Initial weights for control participants were calculated at each distinct CKD onset time as the inverse probability of selection after inclusion of subsequent case participants as potential control participants to simulate incidence density sampling. After rescaling these weights by dividing them by their mean value, we calibrated them to the predicted weights by using the matching factors. This process resulted in the model-adjusted weights for the logistic regression analyses.
Next, we compared 1-year changes in each biomarker between case and control participants, stratified by intervention group. We also compared 1-year changes among case participants in the intensive group versus those in the standard group. Although comparing control participants between intervention groups was not part of our prespecified analytic plan, these data were included for completeness. We examined 1-year changes by modeling the difference (1-year minus baseline) in log 2 -transformed biomarker concentrations by using linear mixed-effects models, adjusting for baseline SBP and both linear and quadratic terms for log 2 -transformed urinary creatinine concentrations. To account for the matched study design, we included case-control pair ID as a random effect and adjusted for the matching variables (age, race, sex, and eGFR). Only participants with complete data for case-control pairs were included in these analyses, which resulted in varying sample sizes across the biomarkers. Predicted (least-squares) means of the change in biomarker and associated 95% CIs were back transformed to estimate the mean ratio of 1-year to baseline levels. Associated Wald tests for differences in the predicted mean changes were used to test significance. The mean changes in each biomarker and the comparisons between groups were presented graphically for ease of communication. We used an interaction term to evaluate whether relative biomarker changes between case and control participants were statistically different between the intervention and standard groups.
P values less than 0.05 were considered statistically significant for all analyses without adjustment for multiple comparisons, because biomarkers were hypothesized to be mutually reinforcing rather than a series of independent tests (14). All analyses were performed with SAS, version 9.4 (SAS Institute), particularly the LOGISTIC procedure for conditional logistic regression analyses and the MIXED procedure for linear mixedeffects models.
Role of the Funding Source
This ancillary study was funded by the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK). The funding source had no involvement in study design, analysis, or production of the final manuscript.
RESULTS
After control participants were matched to incident CKD case participants on age, sex, race, baseline eGFR, and randomization group, additional baseline characteristics and cardiovascular risk factors were well balanced between the case participants and their matched controls ( Table 1 ). The only exception was baseline SBP, which was significantly higher among the case than the control participants within both intervention groups. At 1 year after randomization, persons with incident CKD in both intervention groups had significantly higher serum creatinine concentrations and lower eGFRs than their respective matched controls. In addition, persons in the intensive group were prescribed greater numbers of antihypertensive medications, including angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, at 1 year than those in the standard group. Within the intensive group, the CKD case participants were prescribed significantly more antihypertensive medications and had significantly lower diastolic blood pressures at 1 year than their matched controls.
At baseline, the 9 kidney biomarkers were only weakly intercorrelated (Appendix Table 3 , available at Annals.org); moderate correlations were observed for only 2 biomarker pairs (␣ 1 M and ␤ 2 M [r = 0.53], and KIM-1 and MCP-1 [r = 0.49]), whereas the other pairwise comparisons showed weak associations. We evaluated the association between baseline biomarker concentrations and incident CKD case status, adjusting for baseline SBP and urinary creatinine levels ( Table 2) . Higher ACR and urinary KIM-1 and MCP-1 concentrations were each significantly associated with greater odds of incident CKD. These results were not affected by reweighting of the matched control participants to the broader cohort of non-case participants (Appendix Table 4 , available at Annals.org). In stratifying by intervention group, we observed similar effect sizes in each group, although the associations were not statistically significant in the standard group (Appendix Table 5 , available at Annals.org).
The 1-year biomarker concentrations among case and control participants in each intervention group are presented in Appendix Table 6 (available at Annals .org). We compared the 1-year relative changes in each biomarker between case and control participants and found that persons with incident CKD in the intensive group had relative declines in ACR, IL-18, YKL-40, and uromodulin that differed significantly from the relative changes in matched control participants (Figure) . In the intensive group, the 1-year relative changes in KIM-1, NGAL, ␤ 2 M, and ␣ 1 M levels did not differ significantly between case and control participants, and MCP-1 rel-
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Biomarkers of Kidney Damage and Incident CKD atively increased in case participants. In the standard group, no significant differences in 1-year relative changes were observed between case and control participants for any biomarker. We tested for interactions comparing the case-control differences between the 2 intervention groups and found none to be statistically significant (Appendix Table 7 , available at Annals.org).
At 1 year, the case participants in the standard group had higher values of all 9 biomarkers compared with those in the intensive group, but the difference was statistically significant only for YKL-40 (P = 0.01) (Appendix Table 6 ). We compared the 1-year relative changes in each biomarker between CKD case participants in the intensive group and those in the standard group, adjusting for baseline SBP and urinary creatinine levels, and found significant differences for ACR, ␤ 2 M, ␣ 1 M, YKL-40, and uromodulin ( Figure) . Among case participants, values of all 5 of these biomarkers were lower at 1 year in the intensive group and were either higher or unchanged in the standard group. 
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To determine whether use of renin-angiotensinaldosterone system inhibitors influenced the decrease in ACR, we stratified the case participants in the intensive group by users (n = 90) and nonusers (n = 19) of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers during follow-up until CKD diagnosis. The median reduction in ACR was near unity among these 2 groups (Ϫ33% [interquartile range, Ϫ66% to 25%] vs. Ϫ46% [interquartile range, Ϫ86% to 41%], respectively). Among case participants in the standard group, the change in ACR differed substantially by use of these medications: Ϫ16% (interquartile range, Ϫ68% to 44%) among 23 users versus 85% (interquartile range, 54% to 159%) among 10 nonusers.
DISCUSSION
In this case-control study nested within a trial of persons with hypertension and without CKD at baseline, we used a diverse panel of urinary biomarkers to characterize intrinsic kidney damage among incident CKD case participants in the setting of intensive SBP reduction to less than 120 mm Hg. Our findings demonstrate that despite substantial eGFR declines in participants who developed CKD during SPRINT's first year, incident CKD cases in the setting of intensive blood pressure lowering were not characterized by intrinsic kidney damage; rather, these participants had less injury overall than matched control participants without CKD. In contrast, incident CKD case participants in the standard study group had relatively higher levels of 5 of the 9 biomarkers we evaluated compared with those in the intensive group. These data support the notion that eGFR declines in the setting of intensive blood pressure lowering are generally manifestations of benign changes in renal blood flow.
Although participants did not have clinically diagnosed CKD at baseline, we found that baseline urinary ACR and urinary KIM-1 and MCP-1 concentrations were associated with incident CKD during follow-up. Compared with the baseline characteristics of control participants, those of matched participants with future incident CKD otherwise were distinguished only by higher SBP. These findings suggest that urinary biomarkers may identify persons with subclinical kidney injury who may be at increased risk for subsequent eGFR changes. These findings are consistent with studies in other settings that reported associations of ACR, KIM-1, and MCP-1 with incident CKD and kidney function decline (15-17).
Our comparisons of 1-year biomarker changes also are consistent with previous clinical trials reporting that eGFR declines have divergent associations with cardiovascular disease and mortality, depending on whether they occur during intensive versus standard SBP management (18 -22). For example, a post hoc analysis of the SPS3 (Secondary Prevention of Small Subcortical Strokes) trial found that early eGFR declines within the intensive SBP reduction group were not associated with adverse cardiovascular outcomes, in contrast to eGFR declines within the standard care group, which portended greater cardiovascular risk (23). Likewise, analyses of the MDRD and AASK (African American Study of Kidney Disease and Hypertension) trials found that participants randomly assigned to more intensive SBP lowering had initial elevations in creatinine levels, but lower long-term mortality risk, relative to participants assigned to less intensive management (24, 25). These investigators hypothesized that blood pressure treatment decreases renal blood flow and reduces hydrostatic pressure gradients across the glomerular capillaries, in turn benignly decreasing creatinine clearance and eGFR. Building on these findings, our results suggest that blood pressure lowering may even alleviate hypertensive kidney injury, regardless of changes in serum creatinine levels.
Although we measured a panel of biomarkers to broadly characterize kidney damage, highlighting the unique physiologic domains these biomarkers represent is important. For example, serum albumin, ␣ 1 M, * Per SD increase in log 2 -transformed biomarker concentrations. All models except that for ACR were adjusted for log 2 -transformed urinary creatinine concentrations. All models were adjusted for baseline systolic blood pressure.
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and ␤ 2 M are systemic proteins filtered at the glomerulus and reabsorbed by the proximal tubules. Urinary concentrations of these proteins decreased significantly in the case participants in the intensive group versus those in the standard group at 1 year (26 -28). These relative decreases among case participants in the intensive group may be a direct reflection of reduced renal blood flow and glomerular filtration of these proteins in the setting of intensive blood pressure lowering, independent of renin-angiotensin-aldosterone system inhibitor use. In contrast, the relative elevations among case participants in the standard group may represent impaired tubular absorption of these proteins, a manifestation of true intrinsic kidney damage. The other 6 biomarkers are produced largely within the kidney and released into urine, and 2 of these biomarkers differed significantly in the compari- Figure. One-year percentage changes in levels of 9 urinary biomarkers among incident CKD case participants (black bars) and matched control participants without CKD (gray bars), stratified by randomization group, in SPRINT. 
%
The intensive group had 128 case participants, and the standard group had 34. In each intervention group, 1 control participant was matched to each case participant on age (within 5 y), sex, race, and baseline eGFR (within 5 mL/min/1.73 m 2 ). The 1-y changes were estimated from separate linear mixed models for each biomarker, with adjustment for log 2 -transformed urinary creatinine levels and systolic blood pressure. Error bars denote the 95% CIs. The y-axes are truncated at ±80%. The 95% CI upper bounds for several biomarkers among case participants in the standard group were truncated: The 95% CI upper bounds of 1-y changes in KIM-1, MCP-1, ␤ 2 M, and ␣ 1 M extend to 97%, 89%, 114%, and 163%, respectively. Brackets with P values represent comparisons of 1-y changes between respective groups at bracket tails. P values less than 0.05 were considered statistically significant. The numerical values of the 1-y change and 95% CIs are presented in Appendix Table 6 
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sons of case participants between the 2 randomization groups: YKL-40 and uromodulin decreased in the case participants in the intensive group and remained unaltered or increased in those in the standard group. YKL-40 is produced largely by kidney tubular cells and signifies kidney tubular injury and repair (29, 30). The relative decreases in YKL-40 levels suggest that participants with incident CKD in the setting of intensive blood pressure lowering had less tubular damage than matched control participants and less than case participants in the standard group. However, this pattern was not observed for other traditional markers of tubular injury (for example, IL-18, KIM-1, NGAL, and MCP-1).
The relative decreases in uromodulin levels among case participants in the intensive group that differed significantly from elevations among case participants in the standard group were unexpected. Uromodulin, which is produced in the thick ascending limb of the loop of Henle and the distal tubule, is believed to protect against CKD. When measured at a single time point, higher uromodulin levels were associated with less CKD progression in a previous study (31), although baseline uromodulin levels were not associated with the odds of incident CKD in our current study. We expected to observe relative elevations in uromodulin levels among case participants in the intensive group. However, dynamic changes in uromodulin were not evaluated in previous studies. A possibility exists that lower renal blood flow may lead to a decreased requirement for uromodulin production or secretion. Nonetheless, we acknowledge that this finding may be discrepant with our overall hypotheses. Future studies are necessary to examine the dynamic changes of uromodulin in response to treatments that influence kidney health and its association with outcomes.
Strengths of this study include the matched casecontrol design in a randomized trial setting, which minimized potential confounding. The SPRINT study involved 102 centers across the United States and Puerto Rico, closely followed the participants, and collected creatinine measurements and longitudinal urine samples frequently, which provided a unique opportunity to investigate kidney changes in the context of intensive blood pressure reduction.
We also acknowledge several important limitations. Although the biomarker results exhibit a consistent pattern overall, we cannot explain the biological mechanisms of some of the changes specifically. For example, KIM-1 and NGAL were significantly increased to a similar magnitude in comparisons of case versus control participants. We are uncertain why these biomarkers would increase during follow-up, and to our knowledge, no previous study measured them repeatedly in a similar cohort. In addition, our study lacked power to compare case and control participants who received standard therapy, because only 34 incident CKD cases occurred in this group. This may explain the absence of significant differences in baseline biomarkers in case participants in the standard group as well as significant differences in the 1-year changes between case and control participants in this group. Because we measured biomarkers only at baseline and at year 1, we do not have biomarker concentrations from the precise time of CKD diagnosis. Most incident CKD end points occurred after the 1-year biomarker measurements; thus, concentrations may have been different if measured at the time of incident CKD diagnosis. However, the mean eGFR decline at 1 year was significantly greater among case than control participants in the intensive group (20 vs. 4 mL/min/1.73 m 2 ) and in the standard group (16 vs. 0 mL/min/1.73 m 2 ), so the eGFR had already decreased substantially among the incident CKD case participants at the time of biomarker measurement. If the substantial eGFR declines found among case participants in the intervention group had been associated with intrinsic kidney injury, we should have detected elevations in biomarker concentrations at 1 year. Finally, our findings may not be generalizable to all persons with hypertension, particularly those with diabetes or proteinuria greater than 1 g/d, who were excluded from SPRINT.
Two important and distinct roles for urinary biomarkers emerge from our findings: identifying persons susceptible to CKD by using the baseline concentrations and using changes in the biomarkers to evaluate longitudinal changes in kidney health. The biomarkers that provided baseline prediction of CKD, a potential proxy of kidney reserve, were not the same as those that reflect responses to blood pressure changes. An eventual biomarker panel in clinical care will warrant a collection of proteins that achieve both these objectives. Future work should investigate whether urinary biomarkers can prognosticate and distinguish persons with true tubular injury accompanying eGFR changes in CKD, similar to the use of these biomarkers in acute kidney injury (32, 33).
In conclusion, the perception of a tradeoff between cardiovascular benefits and kidney harms during intensive blood pressure lowering may be misguided. We found that participants with incident CKD in the setting of intensive SBP treatment did not have elevations in kidney damage biomarkers in the first year of treatment; instead, they had relative declines in several biomarkers compared with both matched control and CKD case participants in the standard group. These findings suggest that eGFR reductions observed in the setting of intensive blood pressure lowering are mostly hemodynamic in nature, even among persons who may be inappropriately labeled as having a new diagnosis of CKD. We also demonstrate the limitations of serum creatinine and the potential utility of urinary biomarkers for monitoring kidney health during hypertension treatment, when changes in renal blood flow may confound the clinical interpretation of changes in serum creatinine levels. Ultimately, these findings, in conjunction with the lower cardiovascular disease and mortality risk reported in SPRINT, should reassure clinicians who embark on evidence-based intensive blood pressure lowering for their patients. Note: All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors.
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